Press

Newsroom

Featured articles

ImpriMed Unveils Groundbreaking Cell-Sizing Method for High-Accuracy Feline Lymphoma Characterization in Veterinary Sciences

Business Wire
Learn More β†’

Prognostic Utility of the Flow Cytometry and Clonality Analysis Results for Feline Lymphomas

Veterinary Sciences
Learn More β†’

ImpriMed: Providing Personalized Medicine For Pets With Blood Cancer Diseases In A $1+ Billion Market

Pulse 2.0
Learn More β†’

New AI Tool Guides Canine Cancer Treatment

Today's Veterinary Business
Learn More β†’

Artificial intelligence poised to transform veterinary care

AVMA News
Learn More β†’

New AI service offers personalized drug response predictions for canine patients with cancer

DVM360
Learn More β†’

ImpriMed Launches Innovative AI-Driven Drug Response Predictions (DRP) Service to Guide Tailored Treatments, Meet Rising Demand in Veterinary Oncology

Business Wire
Learn More β†’

Improving Canine Lymphoma Treatment Outcomes by Individualizing Drug Selection using Machine-Learning-Based Predictive Models

Symposium on Artificial Intelligence in Veterinary Medicine (SAVY)
Learn More β†’

ImpriMed to Showcase Groundbreaking AI Research and Applications at Symposium on Artificial Intelligence in Veterinary Medicine (SAVY)

Business Wire
Learn More β†’

Treatment-specific risk stratification of feline lymphoma based on unsupervised clustering of flow cytometry results

World Veterinary Cancer Congress 2024
Learn More β†’

Dramatically increased clinical remission rates and survival times in dogs with high-grade T-cell lymphoma and relapsed B-cell lymphoma in clinical study of AI decision support

World Veterinary Cancer Congress 2024
Learn More β†’

ImpriMed to Present Innovative Research at 2024 World Veterinary Cancer Congress

Business Wire
Learn More β†’

Multimodal machine learning models identify chemotherapy drugs with prospective clinical efficacy in dogs with relapsed B-cell lymphoma

Frontiers in Oncology
Learn More β†’

AI-driven Personalized Medicine for Cancer Care

Precision Medicine World Conference 2024
Learn More β†’

Dog cancer treatment ImpriMed aims to expand its AI technology into human oncology

TechCrunch
Learn More β†’

ImpriMed Raises $23 Million Series A Round to Expand its Revolutionary AI-Powered Cancer Treatment Technology

Business Wire
Learn More β†’

Increased survival and remission rates in prospective study of relapsed B-cell lymphoma patients treated by oncologists using ImpriMed's AI predictions

Veterinary Cancer Society Annual Conference 2023
Learn More β†’

Identification of drug response biomarkers for canine lymphoma in large-scale NGS screen

Veterinary Cancer Society Annual Conference 2023
Learn More β†’